The demand for complex therapeutic proteins is rapidly accelerating, with the bispecific market alone projected to grow to $50B by 2030. While these atypical molecules offer transformative clinical potential, their complexity introduces significant manufacturing challenges, including extended development timelines, low expression levels, and stability issues across production steps. As pipelines grow more sophisticated, the need for standardized, scalable, and de-risked manufacturing strategies has never been greater.
Webinar: New Protein A Purification Technology 
What Makes a Successful Tech Transfer?
